- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Riverain’s Chest X-Ray Comparison Tool Gets FDA Nod
Temporal Comparison software compares current and prior chest X-rays to help identify nodules that may be early-stage lung cancer.
Riverain Technologies, a Dayton, Ohio-based medical technology company, has received FDA 510(k) clearance for its Temporal Comparison software, which compares current and prior chest X-rays and can help identify nodules that may be early-stage lung cancer, the company announced.
The technology targets differences between the X-rays, drawing attention to what could be an emerging or enlarging tumor. The software aligns the two images to produce a difference image, which the company said allows radiologists to identify subtle changes more clearly.
In a study of 422 pairs of chest X-rays, 15 radiologists demonstrated an average of 12.4 percent improvement in sensitivity for actionable solitary pulmonary nodules using the software, compared to results viewing the X-rays side by side, the company said.
The software can be used with Riverain’s Bone Suppression software, which removes the bones from the image to make differences more conspicuous.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
